Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab for severe COVID-19 pneumonia
NCT04463004Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mavrilimumab in COVID-19 pneumonia, sponsored by Virginia Commonwealth University. Started Sep 2020; status: completed.
02
Drugs
mavrilimumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04463004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463004.